This is a renewal application for grant R37 AI36082 Neutralization of primary HIV-1 viruses that was awarded in 2008. The overall goal is a detailed molecular understanding of how neutralizing antibodies, alone and together, inhibit HIV-1 infection of target cells, and how the antigens that they are directed to modulate the antibody response by interacting with dendritic cells and B cells. The work outlined in the proposal will be conducted in Dr. John Moore's laboratory at the Weill Comell Medical College We propose three Specific Aims:
Specific Aim 1 : Mechanism, stoichiometry and kinetic aspects of HIV-1 neutralization by Abs. In this Aim we will use new in vitro neutralization assays to dissect how neutralizing antibodies with different specificities block HIV-1 infection and to quantify the persistent fi-action that survives neutralization. We will use transmembrane-protein mutants to study how differential exposure of epitopes on the Env-glycoprotein complex affect the potency and extent of neutralization.
Specific Aim 2 : Synergy, cooperativity and breadth of HIV-1 neutralization. We will build on our finding of Env-glycoprotein heterogeneity as a source of synergy between neutralizing antibodies. Using new mathematical analyses, we will explore the relationship between synergy and cooperativity and how they affect potency and extent of neutralization of different primary HIV-1 inocula with varying degrees of heterogeneity.
Specific Aim 3 : Induction of immunosuppressive responses by the mannose moieties of gpl20 glycans. We will characterize how gpl20 at high concentrations that may prevail locally after immunization affect the interplay between dendritic cells and lymphocytes, including the secretion of cytokines and B-cell stimulatory factors. The pursuit of these goals will help provide in vitro correlates for which neutralizing antibodies may be most protective in vivo and inform the design of immunogens so that high titers of such antibodies can be induced.
An effective preventive vaccine against HIV-1 infection is important to stop the global AIDS epidemic spreading further. Such a vaccine must induce antibodies that protect against infection by the virus, most probably antibodies that neutralize virus infectivity. In our research program, we will try to determine why some such antibodies are more protective than others, and why they are so difficult to induce by vaccination.
|Ringe, Rajesh P; Ozorowski, Gabriel; Rantalainen, Kimmo et al. (2017) Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. J Virol 91:|
|Ringe, Rajesh P; Ozorowski, Gabriel; Yasmeen, Anila et al. (2017) Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. J Virol 91:|
|Acharya, Kriti; Rashad, Adel A; Moraca, Francesca et al. (2017) Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. Proteins 85:843-851|
|Sullivan, Jonathan T; Sulli, Chidananda; Nilo, Alberto et al. (2017) High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J Virol 91:|
|DeSantis, Michael C; Kim, Jin H; Song, Hanna et al. (2016) Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry. J Biol Chem 291:13088-97|
|Eggink, Dirk; de Taeye, Steven W; Bontjer, Ilja et al. (2016) HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. J Virol 90:10587-10599|
|van Gils, Marit J; van den Kerkhof, Tom L G M; Ozorowski, Gabriel et al. (2016) An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2:16199|
|Klasse, P J; LaBranche, Celia C; Ketas, Thomas J et al. (2016) Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathog 12:e1005864|
|Klasse, P J (2016) How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines 15:295-311|
|Behrens, Anna-Janina; Vasiljevic, Snezana; Pritchard, Laura K et al. (2016) Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep 14:2695-706|
Showing the most recent 10 out of 112 publications